Steven Lichtman
Stock Analyst at William Blair
(2.82)
# 1,540
Out of 5,182 analysts
73
Total ratings
37.74%
Success rate
9.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MMED Minimed Group | Initiates: Outperform | n/a | $13.23 | - | 1 | Mar 31, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $44 → $22 | $18.28 | +20.35% | 2 | Sep 8, 2025 | |
| PODD Insulet | Maintains: Outperform | $324 → $365 | $202.46 | +80.28% | 8 | Sep 8, 2025 | |
| BSX Boston Scientific | Upgrades: Outperform | $118 → $125 | $61.86 | +102.07% | 4 | Sep 8, 2025 | |
| DXCM DexCom | Maintains: Outperform | $95 → $102 | $63.11 | +61.62% | 9 | Jul 31, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $91.40 | +47.70% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $2.57 | +366.93% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $74.67 | +47.31% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $86.42 | +8.77% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $6.76 | +861.54% | 8 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $5.5 | $12.26 | -55.14% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $9.70 | +23.71% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $67.40 | +29.08% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $105 | $5.24 | +1,903.82% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $332.07 | -13.27% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $115.06 | -8.74% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $21.09 | +611.24% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $69.66 | +22.02% | 3 | Sep 4, 2020 |
Minimed Group
Mar 31, 2026
Initiates: Outperform
Price Target: n/a
Current: $13.23
Upside: -
Tandem Diabetes Care
Sep 8, 2025
Maintains: Outperform
Price Target: $44 → $22
Current: $18.28
Upside: +20.35%
Insulet
Sep 8, 2025
Maintains: Outperform
Price Target: $324 → $365
Current: $202.46
Upside: +80.28%
Boston Scientific
Sep 8, 2025
Upgrades: Outperform
Price Target: $118 → $125
Current: $61.86
Upside: +102.07%
DexCom
Jul 31, 2025
Maintains: Outperform
Price Target: $95 → $102
Current: $63.11
Upside: +61.62%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $91.40
Upside: +47.70%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $2.57
Upside: +366.93%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $74.67
Upside: +47.31%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $86.42
Upside: +8.77%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $6.76
Upside: +861.54%
May 9, 2024
Maintains: Outperform
Price Target: $5 → $5.5
Current: $12.26
Upside: -55.14%
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $9.70
Upside: +23.71%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $67.40
Upside: +29.08%
Sep 19, 2023
Reiterates: Outperform
Price Target: $105
Current: $5.24
Upside: +1,903.82%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $332.07
Upside: -13.27%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $115.06
Upside: -8.74%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $21.09
Upside: +611.24%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $69.66
Upside: +22.02%